Peptides in Metabolic Research: What the Published Studies Show
Metabolic research is one of the fastest-moving areas of peptide science — driven partly by the clinical success of GLP-1 receptor agonists and partly by growing interest in non-incretin pathways like AMPK and the GH-IGF-1 axis. This overview covers five research peptides with the most substantial published data in metabolic science: Retatrutide, Tirzepatide, Semaglutide, MOTS-C, and Tesamorelin. For research purposes only. Not for human therapeutic use.
- ✓Retatrutide (triple GIP/GLP-1/glucagon agonist) showed ~24% body weight reduction at 48 weeks in Phase 2 trials — currently in Phase 3 TRIUMPH programme
- ✓Tirzepatide (dual GIP/GLP-1) is the most established dual incretin in clinical use; SURMOUNT-1 showed 22.5% weight reduction at 72 weeks vs 2.4% placebo
- ✓MOTS-C is a mitochondria-derived peptide that activates AMPK, improving insulin sensitivity in rodent models of metabolic dysfunction
- ✓Tesamorelin (GHRH analogue) has Phase 3 data and FDA approval for HIV-associated lipodystrophy — the only GHRH analogue with regulatory approval for a metabolic indication
- ✓All products for research purposes only — October 2024 TGA compounding changes affect GLP-1 class peptides in Australia; see TGA guidance for current regulatory status
In This Article
The Landscape of Metabolic Peptide Research
Metabolic research involving peptides spans several mechanistically distinct pathways. The most clinically validated — and most discussed — are the incretin receptor agonists: GLP-1R agonists (Semaglutide), dual GIP-R/GLP-1R agonists (Tirzepatide), and the triple agonist Retatrutide, which adds glucagon receptor (GCGR) activity to the dual incretin profile. Outside the incretin class, MOTS-C represents a mitochondria-derived approach to metabolic regulation via AMPK, and Tesamorelin addresses visceral adiposity through the GH-IGF-1 axis.
These compounds are not interchangeable — they target different receptor systems, produce different metabolic signatures in research models, and carry different regulatory and compliance considerations in Australia. Understanding the mechanistic distinctions is essential for designing protocols that isolate specific pathways of interest.
Retatrutide — Triple Receptor Agonism in Adiposity Research
Retatrutide (LY3437943) is a triple agonist at GIP, GLP-1, and glucagon receptors — the first compound with this receptor profile to reach Phase 3 clinical trials. The glucagon receptor (GCGR) component is what sets it apart from Tirzepatide: GCGR agonism promotes thermogenesis and hepatic fat oxidation, effects that are otherwise antagonised by the GLP-1 and GIP components in the context of glycaemic control, but which persist as net energy expenditure benefits in adipose tissue and the liver.
The Phase 2 trial (Jastreboff et al., NEJM, 2023) in adults with obesity documented mean body weight reductions of approximately 24% at 48 weeks in the highest dose cohort — numerically greater than available Phase 2/3 data for both Semaglutide and Tirzepatide at comparable timepoints, though cross-trial comparisons are methodologically limited. The TRIUMPH Phase 3 programme is ongoing across obesity, type 2 diabetes, cardiovascular, and MASH/NASH cohorts.
For researchers: Retatrutide's unique GCGR component makes it the most mechanistically distinct of the three GLP-1 class compounds covered here. Research comparing triple versus dual versus single agonism is an active area — particularly for NASH/liver fat endpoints where the GCGR contribution appears most differentiated.
Tirzepatide — Dual GIP/GLP-1 Agonism
Tirzepatide is a dual agonist at the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) — approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management in several jurisdictions. The GIP component is hypothesised to contribute to Tirzepatide's favourable tolerability relative to GLP-1-only agents by modulating GI motility effects, and to produce additional metabolic benefits via adipose tissue GIPR signalling.
The SURMOUNT Phase 3 programme demonstrated mean body weight reductions of 20–22% at 72 weeks in adults with obesity, and robust HbA1c reductions in type 2 diabetes populations. For metabolic research, Tirzepatide is particularly useful as the intermediate compound between GLP-1 monotherapy (Semaglutide) and triple agonism (Retatrutide) — enabling receptor contribution studies where the incremental effect of GIPR activation can be examined separately from GCGR activation.
Semaglutide — The GLP-1 Monotherapy Reference Compound
Semaglutide is a GLP-1 receptor agonist with a C18 fatty acid modification enabling albumin binding and a ~7-day plasma half-life. It is the most clinically validated compound in the incretin class, with Phase 3 data across type 2 diabetes (SUSTAIN programme), obesity (STEP programme), and cardiovascular outcomes (SELECT trial, which showed a 20% reduction in MACE in people with obesity and cardiovascular disease but without diabetes).
In research contexts, Semaglutide serves as the established GLP-1R reference compound — the single-agonist baseline against which dual and triple agonist effects can be compared. The STEP trials documented ~15% body weight reduction at 68 weeks in adults with obesity, providing the comparative benchmark for both Tirzepatide and Retatrutide Phase 2/3 data.
MOTS-C — Mitochondria-Derived Metabolic Regulation via AMPK
MOTS-C is a mitochondria-derived peptide encoded within the 12S ribosomal RNA gene of the mitochondrial genome — making it one of a newly characterised class of mitochondria-derived peptides (MDPs) with systemic signalling functions. Its primary studied mechanism is AMPK (AMP-activated protein kinase) activation, a central energy-sensing enzyme that regulates glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.
Research interest in MOTS-C extends across several metabolic contexts: insulin sensitisation in skeletal muscle (preclinical rodent models with diet-induced obesity), exercise-mimetic effects on muscle metabolism, and age-related metabolic decline. A 2021 study (Lee et al.) documented circulating MOTS-C levels declining with age in humans and showed that MOTS-C administration improved physical performance and metabolic parameters in aged mice — generating interest in its role in ageing-related metabolic dysregulation.
MOTS-C's AMPK mechanism is entirely distinct from incretin receptor signalling — making it a complementary research compound for studies examining non-incretin routes to improved insulin sensitivity and mitochondrial function. It is not subject to the October 2024 TGA GLP-1 compounding changes.
Tesamorelin — GH-Axis Approach to Visceral Adiposity Research
Tesamorelin is a synthetic GHRH analogue — the complete 44-amino acid sequence of native GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. It stimulates pituitary GH secretion via the GHRH receptor, leading to downstream IGF-1 elevation. Unlike CJC-1295, which uses a DAC modification for very long-acting GH stimulation, Tesamorelin has a shorter half-life (~26 minutes), producing more pulsatile GH release that more closely approximates physiological patterns.
Tesamorelin's relevance to metabolic research is partly anchored by its regulatory history: it received FDA approval in 2010 for HIV-associated lipodystrophy — specifically visceral adiposity secondary to antiretroviral therapy — making it the only GH secretagogue with a regulatory approval for a metabolic adiposity indication. Phase 3 data demonstrated significant reductions in visceral adipose tissue (VAT) as measured by CT, with effects specific to visceral (not subcutaneous) fat compartments.
For researchers studying the GH/IGF-1 axis and its relationship to adipose tissue distribution — particularly visceral fat specifically, rather than total body fat — Tesamorelin provides a well-characterised GHRH agonist tool with established clinical reference data.
Metabolic Research Peptides — Quick Reference
| Compound | Receptor Target | Key Research Focus | Human Data |
|---|---|---|---|
| Retatrutide | GIP-R + GLP-1R + GCGR (triple) | Adiposity, MASH/NASH, energy expenditure | Phase 3 ongoing (TRIUMPH) |
| Tirzepatide | GIP-R + GLP-1R (dual) | Adiposity, T2D, incretin axis research | Phase 3 complete (SURMOUNT) |
| Semaglutide | GLP-1R (single) | Adiposity, T2D, cardiovascular outcomes | Phase 3 complete (STEP, SELECT) |
| MOTS-C | AMPK (mitochondria-derived) | Insulin sensitivity, ageing, exercise mimetic | Primarily preclinical |
| Tesamorelin | GHRHR (GH axis) | Visceral adiposity, HIV lipodystrophy | FDA-approved (lipodystrophy); Phase 3 data |
Frequently Asked Questions
Key References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454.
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. [Tesamorelin Phase 3]